Mesoblast Ltd Files Quarterly Report
Ticker: MEOBF · Form: 6-K · Filed: May 1, 2024 · CIK: 1345099
| Field | Detail |
|---|---|
| Company | Mesoblast LTD (MEOBF) |
| Form Type | 6-K |
| Filed Date | May 1, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: quarterly-report, regulatory-filing
Related Tickers: MESO
TL;DR
MESO dropped its quarterly update, check the Appendix 4C for deets.
AI Summary
On April 30, 2024, Mesoblast Limited filed a quarterly Appendix 4C report with the Australian Securities Exchange. This filing is for entities admitted on the basis of commitments and covers the quarter ended April 30, 2024. The report is submitted under Form 6-K to the U.S. Securities and Exchange Commission.
Why It Matters
This filing provides an update on Mesoblast's financial and operational activities for the recent quarter, which is crucial for investors to assess the company's progress and financial health.
Risk Assessment
Risk Level: low — This is a routine quarterly filing and does not contain significant new risks or material adverse information.
Key Players & Entities
- Mesoblast Limited (company) — Registrant
- Silviu Itescu (person) — Chief Executive Officer and Executive Director
- Australian Securities Exchange (company) — Filing recipient
- April 30, 2024 (date) — Filing date
FAQ
What type of report did Mesoblast Limited file on April 30, 2024?
Mesoblast Limited filed a quarterly report for entities admitted on the basis of commitments (Appendix 4C).
Which regulatory body did Mesoblast Limited file this report with in Australia?
Mesoblast Limited filed the report with the Australian Securities Exchange.
What period does the quarterly report cover?
The quarterly report covers the quarter ended April 30, 2024.
Under which SEC form is this information being reported in the US?
This information is being reported under Form 6-K.
Who is the Chief Executive Officer and Executive Director of Mesoblast Limited?
Silviu Itescu is the Chief Executive Officer and Executive Director of Mesoblast Limited.
Filing Stats: 270 words · 1 min read · ~1 pages · Grade level 14.5 · Accepted 2024-04-30 20:30:55
Filing Documents
- a2024-05x01activitystateme.htm (6-K) — 22KB
- exhibit991.htm (EX-99.1) — 29KB
- exhibit992.htm (EX-99.2) — 9KB
- exhibit991001.jpg (GRAPHIC) — 227KB
- exhibit991002.jpg (GRAPHIC) — 251KB
- exhibit991003.jpg (GRAPHIC) — 307KB
- exhibit991004.jpg (GRAPHIC) — 52KB
- exhibit991005.jpg (GRAPHIC) — 118KB
- exhibit991006.jpg (GRAPHIC) — 125KB
- exhibit991007.jpg (GRAPHIC) — 100KB
- exhibit991008.jpg (GRAPHIC) — 108KB
- exhibit991009.jpg (GRAPHIC) — 209KB
- exhibit991010.jpg (GRAPHIC) — 159KB
- exhibit991011.jpg (GRAPHIC) — 116KB
- exhibit992001.jpg (GRAPHIC) — 265KB
- exhibit992002.jpg (GRAPHIC) — 251KB
- 0001345099-24-000045.txt ( ) — 3212KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized. Mesoblast Limited s Paul Hughes Paul Hughes Company Secretary Dated May 1, 2024 INDEX TO EXHIBITS Item 99.1 Appendix 4C of Mesoblast Ltd, dated April 30 , 2024. 99.2 Press release of Mesoblast Ltd, dated April 30, 2024 .